Semaglutide and Vascular Regeneration

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05870462

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05870462
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05870462. Randomized; no masking; primary purpose basic science. Start 2023-04-29 (actual); primary completion 2024-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide and Vascular Regeneration
Acronym
SEMA-VR
Condition
Atherosclerosis
Condition
Cardiovascular Diseases
Condition
Diabetes Mellitus, Type 2
Condition
Obesity
Intervention (Drug)
Semaglutide Pen Injector
Lead sponsor
Canadian Medical and Surgical Knowledge Translation Research Group (class: other)
Collaborator
Unity Health Toronto (class: other)
Collaborator
Western University, Canada (class: other)

Record details

Record id
cardio:ct-nct05870462
Content hash
0f80ea7bf9b29248236fcad995f1ef6351de12a2fcfd3d15e07395f11e13c8b5